|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6775 USD | +2.09% |
|
+0.24% | -49.81% |
| Jul. 09 | Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc | CI |
| Jul. 01 | Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600 | CI |
On February 12, 2022, Damon Silvestry left Progenity, Inc. (the “Company”). Mr. Silvestry's primary responsibilities related to the Company's laboratory operations, which as previously announced have been discontinued or divested.
| 1st Jan change | Capi. | |
|---|---|---|
| -49.81% | 24.35M | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
BIORA THERAPEUTICS, INC. 
